PDCD1 and cancer: Two such immune checkpoints that have garnered particular interest for cancer immunotherapy treatment are programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4); two highly popular immunological checkpoints are CTLA-4 and CD152, respectively.